Supp.Table 1

MicroRNA	NF-KB Binding Sites (hg18)	PhylCRM Score
miR-21	chr17: 55272130-54	152.32
miR-210	chr11: 557736-50	103.43
miR-155	chr21: 25867053-66	170.23

Supp.Table 2

NF-KB binding motif	in miR-155	in miR-21
Sequence	GGAAATTTC C	GGAAAATTC C
Coordinates	chr21:25,867,055-25,867,064	chr17:55,272,130-55,272,139

Supp. Figure 1



Suppl. Figure 1. Validation of microRNA array data by SYBR green real-time PCR analysis. The expression of levels of the differentially expressed microRNAs identified by TLDA microRNA sc reen analysis (Applied Biosystems) was validated by real-time PCR analysis in the same time points. The experiments were performed in triplicate and the data represent mean ± SD.

Supp. Figure 2



Suppl. Figure 2. Neurotensin suppresses microRNA expression through NTR1 in HCT116 and DLD1 colon cancer cells. NTR1 expression was inhibited in HCT116 and DLD1 colon canc er cells by siRNA treatment for 48h; these cells were treated with neurotensin (100 nM) for 6h and the expression levels of miR-125b, miR-139 and miR-148a were assessed by real-time PCR analysis. All the data show mean ± SD of three independent experiments.

Supp. Figure 3



Suppl. Figure 3. NF- B phosphorylation status after neurotensin treatment in colon cancer cells. Evaluation of NF-KB protein expression and phosphorylation levels in HCT116 and DLD1 cells treated with neurotensin (100nM) for 0.5 and 6h.

Supp. Figure 4



Suppl Figure 4. Neurotensin circuit in LoVo colon cancer cells. (A) MicroRNA expression levels in LoVo cells 0.5 and 6h post neurotensin treatment. The expression levels were assessed by real-time PCR analysis for the top seven neurotensin up- and down-regulated microRNAs in NCM460-NTR1 cells. **(B)** NTR1 expression was inhibited in LoVo colon cancer cells by siRNA treatments (siNTR1#1 or siNTR1#2, 100 nM) for 48h; these cells were treated with neurotensin (100 nM) for 6h and the expression levels of miR-21, miR-210 and miR-155 were assessed by real-time PCR analysis. **(C)** Expression levels of miR-21, miR-210 and miR-155, assessed by real-time PCR, in LoVo cells that were treated with a pharmacological inhibitor of NF-KB pathway (BAY-117082, 5uM) or an siRNA negative control (siRNA NC, 100nM) or an siRNA against p65 (sip65, 100nM) for 48h and then treated with neurotensin (100nM) for 6h. **(D)** AKT phosphorylation (s473) levels, assessed by ELISA, in LoVo cells transfected with miR-155 (100nM) or si-PPP2CA (100nM) for 24h.

Supp. Figure 5



Suppl. Figure 5. Correlation between NTR1 expression levels and miR-21 or miR-155 or PTEN or SOCS1 or PPP2CA in normal and colon cancer tissues.